HOME >> MEDICINE >> NEWS
Treatment response to Aricept® (donepezil hydrochloride) not predicted by Apolipoprotein E4 genotype or gender

WASHINGTON, D.C. 11 July, 2000 -- Aricept® (donepezil hydrochloride) demonstrated beneficial effects on cognition and global function over the course of one year in a double-blind, placebo-controlled, multinational study in patients with mild to moderate Alzheimer's disease (AD). In this study, treatment response was not predicted by Apolipoprotein E4 (ApoE4) genotype and/or gender, according to data presented today at the World Alzheimer Congress in Washington D.C.

ApoE is a lipoprotein that carries cholesterol in the blood. The exact role the ApoE4 allele plays in the pathogenesis of AD or in the memory decline of cognitively impaired elderly is unclear presently. Furthermore, much of the evidence concerning a correlation between ApoE4 copy number and the pathological features of AD (e.g. neuronal plaque density and the appearance of neurofibrillary tangles) is contradictory. It has been suggested that patients carrying an ApoE4 allele may have a more severe cholinergic deficit than those who do not.

"The reports of associations between ApoE4 genotype, gender and response to cholinesterase inhibitor therapy in AD patients are conflicting. In this recently completed study, a secondary analysis showed that the treatment response to ARICEPT®, a cholinesterase inhibitor, was not predicted by ApoE4 genotype and/or gender in patients with mild to moderate AD," says Hilkka Soininen, M.D., Ph.D., University of Kuopio, Kuopio, Finland.

This one-year multinational, double-blind, placebo-controlled study enrolled 286 patients with mild to moderate AD from 28 sites in five Northern European countries (Denmark, Finland, Norway, Sweden and The Netherlands). Patients were randomized to receive either ARICEPT® (n=142; 5 mg/day for 28 days, and then 10 mg/day) or placebo (n=144) for one year. The mean age of the patients enrolled in the study was 72.5 (range: 49-88 years).

Outcomes measures included evaluation of global function (the Gottf
'"/>

Contact: Celeste Torello, Pfizer Inc.
212-733-6471
Porter Novelli
10-Jul-2000


Page: 1 2

Related medicine news :

1. Treatment of cardiac lesions without anaesthesic
2. Treatment guidelines for kids with bipolar disorder published
3. University of Washington joins new Autism Treatment Network to provide better medical services
4. Treatment for brain tumor does not always follow recommendations
5. Advances in Skeletal Anabolic Agents for the Treatment of Osteoporosis: A scientific meeting
6. Treatment of ductal carcinoma in situ varies widely in United States
7. Treatment options expand for patients with neuropathic pain
8. Treatment interruption shows no benefit in drug-resistant HIV infection
9. Peanut Allergy: Major Advances in Treatment and Education
10. Release of results of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
11. Treatment helped reduce dose of inhaled corticosteroids while maintaining asthma control

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/24/2016)... , ... May 24, 2016 , ... ... family wealth and to housing, with more advantaged communities providing richer opportunities. Recognizing ... types of interventions: (a) school improvement policies; (b) school choice policies; (c) school ...
(Date:5/24/2016)... ... ... How to Write Error Free Procedures, **Presented by Ginette M. Collazo and ... known to be the major cause of quality and production losses in many industries. ... performance problems can be prevented. , How to Write Error Free Procedures, part two ...
(Date:5/24/2016)... ... ... Mental health watchdog Citizens Commission on Human Rights (CCHR) of ... Thomas Szasz, is continuing its protest against the use of electroshock (ECT) on children ... The opening of the exhibit follows CCHR’s recent protest at the annual convention of ...
(Date:5/24/2016)... , ... (PRWEB) May ... three new members of its Advisory Board. Joining the Grow ... Kusch. “All three of them embody the mission of our organization ... very fortunate to have them as we continue to expand our ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... injury that focuses on repairing the musculoskeletal and neuromuscular systems of the human ... functional restoration, NYDNRehab began providing treatments for physical therapy in New York, including ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... May 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice president ... today. In his new role, Marziani will lead the company,s business development and sales ... improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... May 24, 2016 Open Access ... Clinical Neurophysiology  Elsevier , a world-leading ... services, today announced the launch of Clinical ... journal that focuses on clinical practice issues in clinical ... clinical series, normal values and didactic reviews. It is ...
(Date:5/23/2016)... 2016 Global Paclitaxel Market 2016 ... 12 companies and the Paclitaxel analysis in this study ... industry and its players. This is the ... details the current state of the industry while providing ... applications and industry chain structure. The Paclitaxel market analysis ...
Breaking Medicine Technology:
Cached News: